Last reviewed · How we verify
Methylphenidate extended-release liquid formulation
Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse.
Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, Narcolepsy.
At a glance
| Generic name | Methylphenidate extended-release liquid formulation |
|---|---|
| Also known as | Quillivant extended release |
| Sponsor | Massachusetts General Hospital |
| Drug class | Sympathomimetic amine; CNS stimulant |
| Target | Dopamine transporter (DAT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters for dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The extended-release liquid formulation provides sustained drug delivery over an extended period, allowing for once-daily dosing.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adults
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Abdominal pain
- Nervousness/anxiety
- Tachycardia
- Elevated blood pressure
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: